Bio-Path Holdings
Patents, Design & Utilities
Last updated:
List of all Bio-Path Holdings patents 13 in total
| Status | Patent |
|---|---|
Application | Utility: P-ETHOXY NUCLEIC ACIDS FOR IGF-1R INHIBITION Filling date: 12 Sep 2025 Issue date: 5 May 2022 |
Application | Utility: P-ETHOXY NUCLEIC ACIDS FOR STAT3 INHIBITION Filling date: 12 Sep 2025 Issue date: 28 Apr 2022 |
Application | Utility: P-ETHOXY NUCLEIC ACIDS FOR LIPOSOMAL FORMULATION Filling date: 12 Sep 2025 Issue date: 25 Nov 2021 |
Application | Utility: COMBINATION THERAPY WITH LIPOSOMAL ANTISENSE OLIGONUCLEOTIDES Filling date: 12 Sep 2025 Issue date: 26 Aug 2021 |
Grant | Utility: P-ethoxy nucleic acids for STAT3 inhibition Filling date: 12 Sep 2025 Issue date: 22 Jun 2021 |
Application | Utility: P-ETHOXY NUCLEIC ACIDS FOR BCL2 INHIBITION Filling date: 12 Sep 2025 Issue date: 29 Apr 2021 |
Application | Utility: P-ETHOXY NUCLEIC ACIDS FOR IGF-1R INHIBITION Filling date: 12 Sep 2025 Issue date: 22 Apr 2021 |
Grant | Utility: Combination therapy with liposomal antisense oligonucleotides Filling date: 12 Sep 2025 Issue date: 23 Feb 2021 |
Grant | Utility: P-ethoxy nucleic acids for liposomal formulation Filling date: 12 Sep 2025 Issue date: 26 Jan 2021 |
Application | Utility: P-ETHOXY NUCLEIC ACIDS FOR LIPOSOMAL FORMULATION Filling date: 12 Sep 2025 Issue date: 16 Apr 2020 |
Application | Utility: P-ETHOXY NUCLEIC ACIDS FOR STAT3 INHIBITION Filling date: 12 Sep 2025 Issue date: 6 Feb 2020 |
Application | Utility: P-ETHOXY NUCLEIC ACIDS FOR IGF-1R INHIBITION Filling date: 12 Sep 2025 Issue date: 6 Feb 2020 |
Application | Utility: COMBINATION THERAPY WITH LIPOSOMAL ANTISENSE OLIGONUCLEOTIDES Filling date: 12 Sep 2025 Issue date: 30 Jan 2020 |
Showing 1 to 13 of 13 patents.